Delivering new horizons for heart health
Esperion is an emerging pharmaceutical company focused on developing and commercializing first-in-class, oral, low-density, lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia and other cardiometabolic risk markers.
Many patients with elevated risk of heart disease are unable to benefit from statins, the current leading treatments, due to the side effects caused by these therapies: this is known as statin intolerance. Our lead product candidate, ETC-1002, is a first-in-class orally available small molecule designed to significantly lower elevated levels of LDL-C and improve other cardiometabolic risk markers — without the muscle-related side effects associated with statin use.
Esperion announced positive top-line results from ETC-1002-008, a Phase 2b study evaluating the efficacy and safety of ETC-1002 monotherapy compared with ezetimibe monotherapy in patients with hypercholesterolemia, with or without statin intolerance, in approximately 350 patients.
Our founder, executive chairman and chief scientific officer, Roger Newton, co-discovered the statin marketed as Lipitor® — the most prescribed LDL-C lowering therapy in the world and best-selling drug in the pharmaceutical industry’s history. Learn more about our management team’s track record of success.